05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of cancer; pharmaceutical preparations for the
treatment of inflammation and inflammatory diseases and
disorders; pharmaceutical preparations for the treatment of
the respiratory system; pharmaceutical preparations for the
treatment of the gastrointestinal diseases and disorders;
pharmaceutical preparations for the treatment of
dermatological diseases and disorders, skin conditions,
alopecia, atopic, and dermatitis; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
asthma and other breathing disorders; pharmaceutical
preparations for the treatment of obesity, diabetes,
cardiovascular, central nervous system diseases and
disorders, metabolic disorders, and stroke.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of cancer; pharmaceutical preparations for the
treatment of inflammation and inflammatory diseases and
disorders; pharmaceutical preparations for the treatment of
the respiratory system; pharmaceutical preparations for the
treatment of the gastrointestinal diseases and disorders;
pharmaceutical preparations for the treatment of
dermatological diseases and disorders, skin conditions,
alopecia, atopic, and dermatitis; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
asthma and other breathing disorders; pharmaceutical
preparations for the treatment of obesity, diabetes,
cardiovascular, central nervous system diseases and
disorders, metabolic disorders, and stroke.
3.
ENGINEERING MONOCLONAL ANTIBODIES TO IMPROVE STABILITY AND PRODUCTION TITER
Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.
A module may receive or generate a mask that defines a shape of a feature depicted in a first image. The mask includes first boundary pixels that define an outer perimeter of the feature. The module may identify a transfer area in a second image to which the feature will be transferred and overlay the mask on the transfer area to align the first boundary pixels with second boundary pixels of the second image that define an outer perimeter of the transfer area. The module may define respective gradient values for pixels of the first image within the first boundary pixels of the mask and generate a set of replacement values for pixels of the transfer area based on the second boundary pixels and the respective gradient values. The module may generate the synthetic image by replacing pixel values of the transfer area with the set of replacement values
The disclosure provides processes for preparing Compound C-5, A-5, and Compound B-5, or salts thereof, as described herein. The disclosure also provides Compounds B-5a, B‑4a, and B-3a, or salts thereof, as described herein.
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of cancer; pharmaceutical preparations for the
treatment of inflammation and inflammatory diseases and
disorders; pharmaceutical preparations for the treatment of
the respiratory system; pharmaceutical preparations for the
treatment of the gastrointestinal diseases and disorders;
pharmaceutical preparations for the treatment of
dermatological diseases and disorders, skin conditions,
alopecia, atopic, and dermatitis; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
asthma and other breathing disorders; pharmaceutical
preparations for the treatment of obesity, diabetes,
cardiovascular, central nervous system diseases and
disorders, metabolic disorders, and stroke.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of cancer; pharmaceutical preparations for the
treatment of inflammation and inflammatory diseases and
disorders; pharmaceutical preparations for the treatment of
the respiratory system; pharmaceutical preparations for the
treatment of the gastrointestinal diseases and disorders;
pharmaceutical preparations for the treatment of
dermatological diseases and disorders, skin conditions,
alopecia, atopic, and dermatitis; pharmaceutical
preparations for the treatment of autoimmune diseases and
disorders; pharmaceutical preparations for the treatment of
asthma and other breathing disorders; pharmaceutical
preparations for the treatment of obesity, diabetes,
cardiovascular, central nervous system diseases and
disorders, metabolic disorders, and stroke.
The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
12.
OFFLINE TROUBLESHOOTING AND DEVELOPMENT FOR AUTOMATED VISUAL INSPECTION STATIONS
In a method for replicating performance of an automated visual inspection (AVI) station, a mimic AVI station that performs one or more AVI functions of the AVI station is constructed. One or more container images are captured by an imaging system of the AVI station while a container is illuminated by an illumination system of the AVI station, and one or more additional container images are captured by a mimic imaging system of the mimic AVI station. The method also includes identifying, by one or more processors, one or more differences between the one or more additional container images and the one or more container images, generating, by the one or more processors, a visual indication of the difference(s) and/or one or more suggestions for modifying the mimic AVI station, and modifying the mimic AVI station based on the visual indication.
This disclosure provides a stable cyclodextrin free chlorobutanol carfilzomib formulation in aqueous solution which is suitable for injection, a kit comprising said cyclodextrin free carfilzomib formulation, and methods for preparation of said cyclodextrin free carfilzomib. Such formulation, kit and methods substantially increase the solubility and stability of the carfilzomib in aqueous solution and facilitate both their manufacture and administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A method for reducing the viscosity of a pharmaceutical formulation is provided that utilizes a viscosity-reducing concentration of an excipient selected from the group consisting of the n-acetyl arginine, n-acetyl lysine, n-acetyl histidine, n-acetyl proline and mixtures thereof in combination with a therapeutic protein. A stable pharmaceutical formulation is also provided.
Biomarkers useful for identifying a variety of cancers that are responsive to treatment with a combination therapy comprising pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof and talimogene laherparepvec are provided. Methods of treating cancers that are resistant to monotherapy with pembrolizumab, a pembrolizumab variant or an antigen-binding fragment thereof are provided. Methods of treating a cancer in a subject having a tumor with a low CD8+ density, a low or negative interferon gamma signature, and/or a low or negative PD-L1 status are also provided.
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
16.
SOLID FORMS OF MACROCYCLIC COMPOUNDS AND USES THEREOF
The disclosure provides solid forms of Compound A, as described herein. The disclosure also provides pharmaceutical compositions comprising the disclosed solid forms and methods of using the disclosed solid forms and pharmaceutical compositions (e.g., to treat cancer).
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D. Q61H, Q61L. Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compormds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R. G13D, Q61H. Q61L, Q61R or G12C disorder.
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Providing medical information in the field of cardiovascular
conditions, diseases, and disorders, and treatment thereof;
providing information to patients in the field of
administering medication.
24.
TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
The present invention relates to tetravalent bispecific and tetraspecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the bispecific and tetraspecific antigen binding proteins as well as methods for producing them are also disclosed.
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
25.
DATA AUGMENTATION AND ENCODING OF MULTI-CHAIN PROTEIN STRUCTURES
Described herein are techniques for predicting one or more properties of a multi-chain protein, the multi-chain protein including at least a first chain and a second chain. In some embodiments, the techniques include: obtaining sequence data for the multi-chain protein, the sequence data indicating a first amino acid sequence specifying at least a portion of the first chain and a second amino acid sequence specifying at least a portion of the second chain; generating a concatenated amino acid sequence by concatenating the first amino acid sequence, a linker, and the second amino acid sequence; encoding the concatenated amino acid sequence to obtain a numeric representation of the concatenated amino acid sequence; and processing the numeric representation of the concatenated amino acid sequence using a trained machine learning model to obtain an output indicative of the one or more properties of the multi-chain protein.
The present disclosure provides crystalline and amorphous HCl and HBr salt forms of (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, pharmaceutical compositions, and methods of treating a disease mediated by C5aR inhibition.
C07D 211/60 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
27.
METHOD FOR PREDICTING OSMOLALITY OF PROTEIN SOLUTIONS
The present disclosure relates to methods for purifying proteins of interest using ultrafiltration and/or diafiltration. Specifically, the present disclosure utilizes a more accurate means for estimating the osmolality of the protein solution that has undergone an ultrafiltration and/or diafiltration operation. The method involves a mathematical model, which employs estimation of the osmolarity of the protein mixture based on the activity of water and Norrish constants for each excipient present in the protein mixture.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G16B 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
28.
SOLID STATE FORMS OF (2R,3S)-2-(4-(CYCLOPENTYLAMINO)PHENYL)-1-(2-FLUORO-6-METHYLBENZOYL)-N-(4-METHYL-3-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE-3-CARBOXAMIDE
The present disclosure provides crystalline and amorphous HCl and HBr salt forms of (2R,3S)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide, pharmaceutical compositions, and methods of treating a disease mediated by C5aR inhibition.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07D 211/60 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Described herein are techniques for predicting one or more properties of a multi-chain protein, the multi-chain protein including at least a first chain and a second chain. In some embodiments, the techniques include: obtaining sequence data for the multi-chain protein, the sequence data indicating a first amino acid sequence specifying at least a portion of the first chain and a second amino acid sequence specifying at least a portion of the second chain; generating a concatenated amino acid sequence by concatenating the first amino acid sequence, a linker, and the second amino acid sequence; encoding the concatenated amino acid sequence to obtain a numeric representation of the concatenated amino acid sequence; and processing the numeric representation of the concatenated amino acid sequence using a trained machine learning model to obtain an output indicative of the one or more properties of the multi-chain protein.
Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL monoclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Provided herein are methods of determining a treatment for a subject having a neoplastic disease, said method comprising assaying a sample obtained from the subject for (a) SAC activity, (b) ploidy, (c) WGD, (d) APC/C activity, or (e) a combination thereof. In exemplary embodiments, the treatment determined for the subject comprises, consists essentially of, or consists of a KIF18A inhibitor, when the sample is positive for (a) increased SAC activity, (b) high ploidy, (c) WGD, (d) low APC/C activity, (d) or a combination thereof.
A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
35.
TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH ANTI-TSLP ANTIBODY
The present disclosure, relates, in general, to methods of treating eosinophilic esophagitis (EOE) using an antibody specific for thymic stromal lymphopoietin (TSLP).
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-inteface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
A drug delivery device may include a housing defining a longitudinal axis and having an opening, a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state, a plunger moveable toward a distal end of the drug storage container to expel a drug from the drug storage container, a drive mechanism operably coupled to the plunger, at least one cavity formed in a wall of the housing to permit a user to view the drug storage container through the at least one cavity, and a window disposed over the at least one cavity and configured to protect the drug in the drug storage container from wavelengths of light in an ultraviolet (UV) range, a visible range, and/or an infrared range.
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
The present disclosure, relates, in general, to methods of treating eosinophilic esophagitis (EOE) using an antibody specific for thymic stromal lymphopoietin (TSLP).
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmacy services; online retail pharmacy services; mail order pharmacy services; online retail store services featuring pharmaceuticals; online retail pharmacy services for the ordering, purchase, and delivery of pharmaceuticals; pharmaceutical services, namely, processing prescription orders Platform as a service featuring computer software to permit users to identify, request and receive pharmacy products
44.
RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
An injector includes a housing having a syringe assembly and an actuating mechanism at least partially disposed within the housing. The syringe assembly includes a syringe barrel that stores a medicament to be injected into a user, a needle assembly, and a filter member disposed adjacent to the needle assembly. The actuating mechanism is operatively coupled to the syringe assembly and includes a torque spring that exerts a torque to urge the medicament through the filter member to be injected into the user. The actuating mechanism further includes a damper mechanism that exerts an opposing force to dampen the motion exerted by the torque spring.
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
46.
TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not limited to lung cancer, pancreatic cancer, colorectal cancer, and solid tumors. In particular, the disclosure provides compounds of Formula (I):, and pharmaceutically acceptable salts thereof, wherein the substituents are as described.
C07D 493/22 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Pharmacy services; online retail pharmacy services; mail order pharmacy services; online retail store services featuring pharmaceuticals; online retail pharmacy services for the ordering, purchase, and delivery of pharmaceuticals; pharmaceutical services, namely, processing prescription orders Platform as a service featuring computer software to permit users to identify, request and receive pharmacy products
48.
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.
Disclosed herein are heavy-chain antibodies having activity as agonists of the dimeric interleukin‑2 receptor, pharmaceutical compositions comprising the heavy-chain antibodies, and methods of treating certain disorders, such as cancer, including but not limited to, small cell lung cancer. Also disclosed herein are methods of treating DLL3-expressing cancers comprising the administration of a T-cell engaging molecule that binds to DLL3 and an IL-2-based therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, providing on-line access to podcasts, videos and educational information, including links to guides, articles, and resources in the field of health, healthcare, and diseases to help improve the quality of post-fracture osteoporosis care
51.
RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD), are also described.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The invention is directed to a method of treating pediatric osteogenesis imperfecta comprising administering an anti-sclerostin antibody to the subject in an amount ranging from 1 mg/kg to 10 mg/kg.
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p. ex. cholécalciférol, vitamine D3
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Disclosed herein are heavy-chain antibodies having activity as agonists of the dimeric interleukin-2 receptor, pharmaceutical compositions comprising the heavy-chain antibodies, and methods of treating certain disorders, such as cancer, including but not limited to, small cell lung cancer. Also disclosed herein are methods of treating DLL3-expressing cancers comprising the administration of a T-cell engaging molecule that binds to DLL3 and an IL-2-based therapy.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Needle shield removers, drug delivery devices, and associated methods are provided that include a tubular body formed from a sheet with a closure having from a plurality of teeth extending laterally outwardly from one longitudinal edge of the sheet and a plurality of grooves extending laterally inwardly into the sheet of material from a second longitudinal edge of the sheet. The plurality of teeth are frictionally received within the plurality of grooves to thereby hold the body in a tubular configuration. The needle shield removers can further include a first plurality of barbs arrayed around a circumference of the body adjacent to a first end thereof and a second plurality of barbs arrayed around a circumference of the body adjacent to a second end thereof.
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c.-à-d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p. ex. automatiques
Provided herein is a powder comprising a live, attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, a sugar alcohol, a source of phosphate, a source of chloride, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids. In exemplary aspects, the powder is a lyophilizate of a liquid composition. Related liquid compositions, methods of preparing an oncolytic virus for administration and methods of treating melanoma are also provided herein.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
56.
METHOD OF ASSESSING STOPPER MOVEMENT IN A DRUG DELIVERY DEVICE
A method of assessing stopper movement in a syringe is provided, the syringe comprising a syringe barrel and a stopper movably disposed within the syringe barrel. The method comprises inoculating a biological particulate through an open proximal end of the syringe barrel such that the biological particulate covers at least a portion of an interface between a proximal face of the stopper and an inner wall of the syringe barrel. A cavity of the syringe contains a fill volume of liquid. Afterwards, the method comprises subjecting the syringe to one or more conditions, extracting the fill volume of liquid from the cavity of the syringe, performing a sterility test on the extracted fill volume of liquid, and determining stopper movement in the syringe based on the sterility test.
Described herein are methods of treating MTAP-null gastrointestinal cancer in a patient comprising administering to the patient a PRMT5 inhibitor, gemcitabine, and paclitaxel (e.g., nab-paclitaxel), or a PRMT5 inhibitor and mFOLFIRINOX. Also described herein are methods of treating MTAP-null gastrointestinal cancer in a patient comprising administering to the patient a PRMT5 inhibitor, gemcitabine, cisplatin, and an anti-PD 1 antibody or an anti-PDL1 antibody.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
Described herein are methods of treating a MTAP-null lung cancer in a patient comprising administering to the patient a PRMT5 inhibitor and an anti-PD1 antibody, optionally in combination with carboplatin and either paclitaxel or pemetrexed. Further described herein are methods of treating a MTAP-null cancer in a patient also suffering from brain metastases comprising administering to the patient a PRMT5 inhibitor.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/555 - Composés hétérocycliques contenant des métaux lourds, p. ex. hémine, hématine, mélarsoprol
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′:
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′:
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G13D, Q61H, Q61L or G12C. The compounds have a general Formula I′:
wherein the variables of Formula I′ are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5383 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
C07D 471/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes du système condensé, au moins un cycle étant un cycle à six chaînons avec un atome d'azote, non prévus dans les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
The present disclosure relates to improved GLP-1 receptor agonist polypeptides and molecules comprising these improved GLP-1 receptor agonist polypeptides, such as molecules comprising one or more GLP-1 receptor agonist polypeptides conjugated to an anti- gastric inhibitory peptide receptor (GIPR) antibody. The present disclosure is also directed to the use of these improved GLP-1 receptor agonist polypeptides and conjugate molecules comprising these polypeptides for treating or preventing obesity, an obesity related condition, type 2 diabetes, and/or a type 2 diabetes related condition.
The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
A61K 31/451 - Pipéridines non condensées, p. ex. pipérocaïne ayant un carbocycle lié directement à l'hétérocycle, p. ex. glutéthimide, mépéridine, lopéramide, phencyclidine, piminodine
C07C 309/04 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone acycliques d'un squelette carboné acyclique saturé contenant un seul groupe sulfo
C07C 309/25 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un squelette carboné
C07D 211/76 - Atomes d'oxygène liés en position 2 ou 6
C07D 211/94 - Atome d'oxygène, p. ex. N-oxyde de pipéridine
C07D 491/048 - Systèmes condensés en ortho avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène le cycle contenant de l'oxygène étant à cinq chaînons
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
Provided herein are improved processes for the preparation of a carbohydrate targeting moiety and its intermediates (I).
Provided herein are improved processes for the preparation of a carbohydrate targeting moiety and its intermediates (I).
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
C07C 231/14 - Préparation d'amides d'acides carboxyliques par formation de groupes carboxamide combinée avec des réactions n'impliquant pas les groupes carboxamide
C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
C07H 1/00 - Procédés de préparation des dérivés du sucre
C07H 15/12 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'azote d'un radical saccharide
Disclosed herein are ultrafiltration/diafiltration (UF/DF) methods comprising the use of diafiltration buffer concentrates, as well as UF/DF methods in which a composition comprising a recombinant protein is concentrated by an ultrafiltration step to a recombinant protein concentration above an intended concentration following a subsequent diafiltration step.
Disclosed herein are ultrafiltration/diafiltration (UF/DF) methods comprising the use of diafiltration buffer concentrates, as well as UF/DF methods in which a composition comprising a recombinant protein is concentrated by an ultrafiltration step to a recombinant protein concentration above an intended concentration following a subsequent diafiltration step.
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
71.
METHOD OF TREATING BRAIN METASTASES IN SUBJECTS WITH A DLL3-POSITIVE CANCER
The disclosure provides a method of treating brain metastases in a human subject with a DLL3-positive cancer. The method comprises administering to the subject an anti-DLL3 agent comprising a first binding domain that binds to human DLL3 on the surface of a target cell and a second binding domain that binds to human CD3 on the surface of a T cell, wherein the anti-DLL3 agent is administered at a dose of from 3 mg to 200 mg once a week, once every two weeks, or once every three weeks.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Disclosed herein are compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C. The compounds have a general Formula (I): (I) or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a KRAS G12D, G12V, G12A, G12S, G12R, G13D, Q61H, Q61L, Q61R or G12C disorder.
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus dans les groupes , , ou dans lesquels le système condensé contient au moins quatre hétérocycles
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2 (1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The present invention relates to binding constructs comprising a domain which binds to MAGEB2. Moreover, the invention provides polynucleotides encoding the binding constructs, a vector comprising said polynucleotides and a host cell transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the binding constructs, methods of treatment using the binding constructs, diagnostic uses of the binding constructs, and kits comprising the binding constructs.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The disclosure provides a heteromultimer comprising a first heterodimer that binds to human delta-like ligand 3 (DLL3) and a second heterodimer that binds to human CD3, which can bind to DLL3-expressing cancer cells. The disclosure also provides methods of treating a DLL3-expressing cancer in a subject in need thereof, which comprises administering to the subject an effective amount of the heteromultimer or a composition comprising the heteromultimer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
New formats of multispecific molecules are described, as well as their methods of making. Additionally, uses in therapeutic indications are also described.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
78.
SUSTAINABLE AND MODULAR PACKAGING SYSTEMS FOR CONTAINERS FOR PHARMACEUTICAL USE
Systems for packaging container(s) is disclosed. The system comprises a carton having a storage configuration where the carton is substantially flat and an assembled configuration. The carton comprises a bottom box, a lid coupled to the bottom box, a first flap extending from the first sidewall of the bottom box, and a second flap extending from the second sidewall of the bottom box. The first and second flaps define a set of cavities. The system also comprises an insert configured to be disposed within the bottom box of the carton. The insert has a storage configuration where the insert is substantially flat and an assembled configuration. The insert defines at least one cavity dimensioned to house at least one container.
B65D 5/50 - Éléments internes de support ou de protection du contenu
B65D 5/10 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p. ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en pliant ou montant un seul flan pour former un corps tubulaire avec ou sans pliage subséquent, ou par addition d'éléments séparés, pour fermer les extrémités du corps avec les fermetures d'extrémité formées par pliage interne de pattes s'emboîtant l'une dans l'autre et articulées au corps tubulaire
B65D 5/54 - Lignes de moindre résistance facilitant l'ouverture des réceptacles ou leur division en parties séparées, par découpage ou déchirement
79.
CANNABINOID TYPE 1 RECEPTOR BINDING PROTEINS AND USES THEREOF
Described herein are anti-CB1 (e.g., huCB1) antibodies and antigen binding fragments, compositions comprising the same and their use for the treatment of various disorders or diseases such as obesity and its comorbidities, chronic kidney disease, liver disease (e.g., NAFLD), and NASH.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Disclosed herein are polypeptides having activity as agonists of a glucagon receptor (“GCGR”), molecules comprising such polypeptides and a half-life extending domain (e.g., an Fc-containing polypeptide), including molecules comprising an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor (“GIPR”), pharmaceutical compositions comprising such polypeptides and molecules, and methods of using such polypeptides, molecules, and pharmaceutical compositions in weight management and the treatment of certain disorders such as obesity.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
81.
SUSTAINABLE AND MODULAR PACKAGING SYSTEMS FOR CONTAINERS FOR PHARMACEUTICAL USE
Systems for packaging container(s) is disclosed. The system comprises a carton having a storage configuration where the carton is substantially flat and an assembled configuration. The carton comprises a bottom box, a lid coupled to the bottom box, a first flap extending from the first sidewall of the bottom box, and a second flap extending from the second sidewall of the bottom box. The first and second flaps define a set of cavities. The system also comprises an insert configured to be disposed within the bottom box of the carton. The insert has a storage configuration where the insert is substantially flat and an assembled configuration. The insert defines at least one cavity dimensioned to house at least one container.
B65D 5/02 - Réceptacles de section transversale polygonale rigides ou semi-rigides, p. ex. boîtes, cartons ou plateaux, formés en pliant ou montant un ou plusieurs flans de papier en pliant ou montant un seul flan pour former un corps tubulaire avec ou sans pliage subséquent, ou par addition d'éléments séparés, pour fermer les extrémités du corps
B65D 5/50 - Éléments internes de support ou de protection du contenu
A drug delivery device may include a housing having an opening, a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state, a plunger moveable toward a distal end of the drug storage container to expel a drug from the drug storage container, a guard moveably positioned adjacent to the opening, and a drive mechanism including a releaser member, a plunger guide, and a guard extension. The device may also include a container holder configured to support the drug storage container. The container holder may have a substantially tubular body portion and a pair of arms extending axially from a proximal end of the body portion, and the arms may be configured to abut a distal end surface of the guard extension to at least partially support the guard extension in at least a pre-delivery state.
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
83.
GLUCAGON RECEPTOR AGONISTS, CONJUGATED TO GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANTIBODIES
Disclosed herein are polypeptides having activity as agonists of a glucagon receptor ("GCGR"), molecules comprising such polypeptides and molecules comprising an antibody that specifically binds to a glucose-dependent insulinotropic polypeptide receptor ("GIPR"), pharmaceutical compositions comprising such polypeptides and molecules, and methods of using such polypeptides, molecules, and pharmaceutical compositions in weight management and the treatment of certain disorders such as obesity.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
84.
DUAL SELECTION EXPRESSION VECTOR SYSTEMS FOR MULTI-CHAIN BIOLOGICS
Dual selection expression vector systems in which one vector employs a metabolic selectable marker and the other employs an antibiotic resistance selectable marker, compositions and mammalian host cells comprising such expression vector systems, and methods of using the foregoing in the expression of recombinant proteins, including polypeptides comprising three or four unique polypeptide chains, are provided.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
86.
METHOD FOR EXTERNAL STERILIZATION OF DRUG DELIVERY DEVICE
A method of externally sterilizing a drug delivery device utilizing Nitrogen Dioxide (NO2) is provided, including placing the drug delivery device in a sterilization chamber, introducing into the chamber a dose of NO2 having a concentration of between about 2 and 20 milligrams per Liter by applying a vacuum level of between about 10 and 600 Torr and holding the vacuum level for a dwell time of between about 2 and 20 minutes, repeating the step of introducing into the chamber a dose of NO2 for a number of pulses between about 1 and 24, purging the sterilization chamber of at least substantially all of the NO2, and aerating the sterilization chamber.
A61L 2/20 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances gazeuses, p. ex. des vapeurs
A drug delivery device may include a housing having an opening, a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state, a plunger moveable toward a distal end of the drug storage container to expel a drug from the drug storage container, a guard moveably positioned adjacent to the opening, and a drive mechanism including a releaser member, a plunger guide, and a guard extension. The device may also include a container holder configured to support the drug storage container. The container holder may have a substantially tubular body portion and a pair of arms extending axially from a proximal end of the body portion, and the arms may be configured to abut a distal end surface of the guard extension to at least partially support the guard extension in at least a pre-delivery state.
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
91.
METHODS OF TREATING GRAFT VERSUS HOST DISEASE USING IL-2 MUTEINS
Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations and substances for the treatment
of cancer and cardiovascular diseases and disorders;
pharmaceutical preparations and substances for the treatment
of oncological diseases and disorders; pharmaceutical
preparations for the treatment of gastric and
gastro-esophageal diseases, conditions or maladies; other
pharmaceutical preparations.
94.
METHODS OF TREATING HEART FAILURE WITH CARDIAC SARCOMERE ACTIVATORS
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The disclosure provides a method of preparing a lyophilized protein composition, the method comprising (a) inducing ice nucleation in a liquid protein composition in a vial exposed to a first temperature of about −15° C. to about −5° C. for about 30 minutes to about five hours; (b) exposing the vial to a second temperature of about −25° C. to −50° C. for a second period of time; and (c) drying the composition of (b) at a third temperature of about 0° C. to about 40° C., resulting in a vial comprising a lyophilized protein composition having a fill aspect ratio of greater than or equal to about 0.75. The disclosure further provides a lyophilized protein composition prepared via the method described herein.
An automated visual inspection (AVI)-based method may include: generating, using an imaging unit, image data of a product; receiving, at a first image analysis hardware unit, the image data from a hardware image splitter; analyzing, using the first image analysis hardware unit, the image data for product defects using a first visual inspection analysis; generating, using the first image analysis hardware unit, first image processing metadata based on the first visual inspection analysis; receiving, at an image storage hardware unit, the image data from the hardware image splitter; storing, using the image storage hardware unit, the image data into a buffer; receiving, at an image storage hardware unit, the first image processing metadata; and/or associating, using the image storage hardware unit, the inspection metadata that includes the first image processing metadata with the image data.
Computer vision techniques for configuring a robot having a robotic arm to interface with equipment to perform a task. The techniques include: capturing at least one image of the equipment: determining a position of a first alignment feature in the at least one captured image: determining, using the position of the first alignment feature in the at least one captured image, an alignment difference between a current alignment of the robot and the equipment with respect to a prior alignment of the robot and the equipment; and configuring the robot to interface with the equipment based on the alignment difference.
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
H04N 23/695 - Commande de la direction de la caméra pour modifier le champ de vision, p. ex. par un panoramique, une inclinaison ou en fonction du suivi des objets
A drug delivery device may include a housing defining a longitudinal axis and having an opening and a drug storage container including a delivery member having an insertion end configured to extend at least partially through the opening during a delivery state. The device may also include plunger moveable toward the distal end of the drug storage container to expel a drug from the drug storage container through the delivery member, the plunger including a body portion having an inner wall defining an axial chamber and an outer wall cooperating with the inner wall to define a body thickness. The device may further include a plunger biasing member disposed at least partially within the axial chamber, the plunger biasing member configured to urge the plunger toward the distal end of the drug storage container.
A61M 5/315 - PistonsTiges de pistonGuidage, blocage, ou limitation des mouvements de la tigeAccessoires disposés sur la tige pour faciliter le dosage
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
100.
METHODS FOR MODULATING MONOCLONAL ANTIBODY CHARGE VARIANTS
The present invention relates to methods of modulating the charge variant profile of a recombinantly produced monoclonal antibody by altering bioreactor media hold durations. Methods of increasing product yield and titer by manipulating media hold durations are also described.
